WASHINGTON, D.C. (September 13, 2021) — Polly Webster is joining the Association for Accessible Medicine as Vice President, Federal Affairs. As a senior strategist and lobbyist, she will represent AAM and its member companies’ interests before Congress and the White House. She will develop short- and long-term goals in support of the federal affairs strategy and lead the promotion of AAM’s objectives through advocacy while preserving and enhancing the association’s important relationships on Capitol Hill.
We are excited to welcome Polly to the team and to be able to bring someone of her caliber to AAM, said Erik Komendant, Senior Vice President of Government affairs.
Polly’s expertise in prescription drug policy, experience working in the House and Senate, and ability to work collaboratively across a diverse set of stakeholders will help advance AAM’s priorities to increase patient access to generic and biosimilar medicines.
Polly came to AAM from Kaiser Permanente, where as Principal Policy Advisor, Government Relations, she led the organization’s work on prescription drug policy and regulations. Polly also served as Health Policy Director for Congresswoman Diana DeGette (D-CO), Health Policy Fellow on the Democratic Senate Committee on Finance and with Senator Jay Rockefeller (D-WV).
Polly received her Bachelors from Denison University, her Master of Public Health from The George Washington University and her law degree from Georgetown University.
AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 20 percent of total drug spending.
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at www.biosimilarscouncil.org.